This is also supported by a mouse study showing that propranolol, a β2-AR antagonist, potentiates the antitumor effects of radiotherapy in gastric cancer by inhibiting NF-κB expression and its downstream genes: VEGF, EGFR, and COX-2 [107]. This evidence concerns the gene ADRB2 and gastric cancer.